Note: IMPACT is Trial 3 of the Prescribing Information. BREO 100 is fluticasone furoate/vilanterol 100/25 mcg (FF/VI) and ANORO is umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI), the comparator names the label uses. Table 5 lists, for each arm, n, the mean annual rate, the rate ratio vs. comparator (95% CI), the percent reduction (95% CI), and the P value.
Does Trelegy reduce severe (hospitalized) COPD exacerbations vs Breo and Anoro (IMPACT)?
Note: IMPACT is Trial 3 of the Prescribing Information. BREO 100 is fluticasone furoate/vilanterol 100/25 mcg (FF/VI) and ANORO is umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI), the comparator names the label uses. The label defines a severe exacerbation as one requiring hospitalization or resulting in death.
Does Trelegy delay the first COPD exacerbation vs Breo and Anoro (IMPACT)?
Note: IMPACT is Trial 3 of the Prescribing Information. BREO 100 is fluticasone furoate/vilanterol 100/25 mcg (FF/VI) and ANORO is umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI), the comparator names the label uses.
How much does Trelegy improve COPD lung function vs Breo and Anoro (IMPACT)?
Note: IMPACT is Trial 3 of the Prescribing Information. BREO 100 is fluticasone furoate/vilanterol 100/25 mcg (FF/VI) and ANORO is umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI), the comparator names the label uses. The measure is the change from baseline in trough FEV1 at Week 52.
Does Trelegy improve COPD quality of life vs Breo and Anoro (IMPACT)?
Note: IMPACT is Trial 3 of the Prescribing Information. BREO 100 is fluticasone furoate/vilanterol 100/25 mcg (FF/VI) and ANORO is umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI), the comparator names the label uses. SGRQ is the St. George's Respiratory Questionnaire; a responder had a decrease from baseline of 4 or more in total score.
Do COPD patients on Trelegy use less rescue medication (IMPACT)?
Note: Trials 1 and 2 tested umeclidinium added to fluticasone furoate/vilanterol from separate inhalers. Table 4 gives, for each trial, n, then the difference from placebo + FF/VI in trough FEV1 and in weighted mean FEV1 (0-6 h), with each 95% CI on the line below.
How soon did Trelegy's components improve COPD lung function vs FF/VI (Trials 1, 2)?
Note: The passage concerns Trials 1 and 2, which tested umeclidinium added to fluticasone furoate/vilanterol, the components of TRELEGY ELLIPTA, against placebo added to fluticasone furoate/vilanterol.
How much did Trelegy improve COPD lung function vs Symbicort Turbuhaler (FULFIL)?
On the page, select: See lung function improvement at 52 weeks (extension data)
Note: The 171 mL difference is at Week 24 against SYMBICORT TURBUHALER 400/12, the ICS/LABA comparator in FULFIL. The Week 52 figures come from the extension phase.
Does Trelegy improve COPD quality of life vs Symbicort Turbuhaler (FULFIL)?
On the page, select: See quality-of-life improvements at 52 weeks (extension data)
Note: The page presents the Week 24 SGRQ results in an image only. The Week 52 figures come from the extension phase. SYMBICORT TURBUHALER 400/12 is a non-US budesonide/formoterol formulation.
Did Trelegy reduce COPD exacerbations vs Symbicort Turbuhaler (FULFIL)?